Hormone-sensitive Prostate Cancer
📧 Sign up to get email alerts when something new happens for Hormone-sensitive Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
A Japanese trial assessing safety and effectiveness of combining darolutamide with androgen deprivation therapy and docetaxel in routine med…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer
This ClinicalTrials.gov study aims to learn about the real-world safety of darolutamide in participants with metastatic hormone-sensitive pr…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia
This is a Bayer-sponsored observational clinical trial in Australia to learn how medicines that block male hormones are used in people with …
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
This is an observational study in Korea assessing the safety of darolutamide in men with prostate cancer, including non-metastatic castratio…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer [Phase 1]
This is a Phase 1 clinical trial evaluating Pasritamig (JNJ-78278343) in combination with other agents for metastatic prostate cancer, curre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
The document is a clinical trial update for a study evaluating androgen deprivation therapy plus apalutamide or enzalutamide in metastatic h…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care
This is an observational clinical trial in Canada assessing treatment patterns for metastatic hormone-sensitive prostate cancer in routine m…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
A real-world observational study in U.S. urology clinics to examine how darolutamide and other androgen receptor pathway inhibitors are used…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) [Phase 1, Phase 2]
A Phase I/II open-label trial evaluating Tulmimetostat in combination with darolutamide versus darolutamide, and Tulmimetostat with abirater…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
A Bayer-sponsored real-world study evaluates how men with advanced, metastatic hormone-sensitive prostate cancer respond to darolutamide in …
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating ASP5541 in participants with prostate cancer, including metastatic castration-resistant and metastatic h…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: PROCARE - PROstate Cancer Real World Evidence Registry
PROCARE is a prostate cancer real-world evidence registry that is currently recruiting participants, collecting data across multiple disease…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [Phase 3]
An international Phase 3 trial compares 177Lu-PSMA-617 plus standard of care versus standard of care alone in men with metastatic hormone-se…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). [Phase 1, Phase 2]
This entry describes a Phase Ib/IIa dose-escalation and expansion trial of the radiopharmaceutical [212Pb]Pb-ADVC001 for metastatic prostate…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany
This clinical trial update discusses using darolutamide in combination with hormone therapy for men with advanced, metastatic hormone-sensit…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer [Phase 1]
This clinical trial update describes a Phase 1 study evaluating Xaluritamig in combination with androgen receptor pathway inhibitors in meta…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression [EARLY_Phase 1]
A Phase 1 study at Beth Israel Deaconess Medical Center is evaluating androgen receptor signaling and PSMA expression in prostate cancer. Th…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer [EARLY_Phase 1]
An early-phase 1 trial is evaluating LC-K76 for safety and efficacy in metastatic prostate cancer. The study targets metastatic hormone-sens…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer [Phase 3]
A Phase III clinical trial evaluating rezvilutamide for metastatic hormone-sensitive prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
This clinical trial assesses whether minimal residual disease can predict therapeutic efficacy in metastatic hormone-sensitive prostate canc…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. [Phase 3]
This clinical trial update outlines the Phase III REINFORCE trial evaluating intensification with docetaxel plus apalutamide in metastatic h…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer [Phase 2]
A Phase 2 clinical trial (CONVERT-HB1) evaluating radical prostatectomy after systemic therapy for patients with high-volume metastatic horm…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer
This clinical trial update describes a study investigating quality of life, functional, and cognitive outcomes in patients with metastatic h…
-
CLINICAL_TRIALS research · 2025-11-05Clinical Trial Update: PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer [Phase 4]
Clinical trial update for a Phase 4 study (PSMAtrack) assessing PSMA-PET imaging changes during initial therapy for metastatic hormone-sensi…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide [Phase 2]
Phase 2 clinical trial evaluating the effect of androgen receptor–directed therapies (darolutamide or enzalutamide) on cognitive function in…